There is a variable response of thyroid cancers to PD-L1 inhibition because of genetic mutations present in ATC, creating the need for further research focused on identifying biomarkers that may predict which patients will benefit from this type of therapy. Here, CD274 is linked to thyroid gland carcinoma.